Altimmune Earnings Estimates, EPS & Revenue | NASDAQ:ALT

Comments

Altimmune Inc Earnings Estimates

ALTNASDAQ

Trade with Public

$3.59

0.092.57%

Last update: Mar 16, 9:24 AM

Overview NewsEarningsOptions Analyst Ratings Insider Trades Short Interest Stock Report

Altimmune Earnings Estimates, EPS & Revenue | NASDAQ:ALT

Altimmune (ALT) is scheduled to report Q1 earnings on May 12, 2026. Analysts estimate EPS of $-0.25 and quarterly revenue of $1.11K.

In the most recent quarter (Q4), Altimmune reported EPS of $-0.27, missing estimates of $-0.25 by 0.08%. Revenue came in at $26.00K, exceeding the estimate of $560.00 by 45.43%.

Over the last 4 quarters, Altimmune has averaged an EPS surprise of 0.19% and a revenue surprise of 20.43%.

Earnings Date

May 12

EPS Estimate

$-0.250

Quarterly Revenue Estimate

$1.11K

Annual Revenue
(as of Dec 31)

$41.00K

Altimmune Earnings History

Analyze the earnings history of Altimmune using advanced sorting and filters.

Loading calendar...

Altimmune (ALT) Earnings Per Share

The chart below shows Altimmune's reported EPS compared to analyst estimates over recent quarters.

Altimmune (ALT) Revenue

The chart below shows Altimmune's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is Altimmune (NASDAQ:ALT) reporting earnings?

Altimmune (ALT) is scheduled to report earnings on May 12, 2026. The last reported earnings were for reported on March 5, 2026 for Q4.

What were the latest earnings per share (EPS) for Altimmune (NASDAQ:ALT)?

The Actual EPS was $-0.27, which missed the estimate of $-0.25.

What were Altimmune’s (NASDAQ:ALT) revenues?

The Actual Revenue was $26.00K, which beat the estimate of $560.00.

People Also Watch

4D Molecular Therapeutics Inc

Monopar Therapeutics Inc

Eupraxia Pharmaceuticals Inc

Lexeo Therapeutics Inc

NASDAQ:LXEO

$6.68

0.30%

Altimmune Earnings Estimates, EPS & Revenue | NASDAQ:ALT

Altimmune (ALT) is scheduled to report Q1 earnings on May 12, 2026. Analysts estimate EPS of $-0.25 and quarterly revenue of $1.11K.

In the most recent quarter (Q4), Altimmune reported EPS of $-0.27, missing estimates of $-0.25 by 0.08%. Revenue came in at $26.00K, exceeding the estimate of $560.00 by 45.43%.

Over the last 4 quarters, Altimmune has averaged an EPS surprise of 0.19% and a revenue surprise of 20.43%.

Earnings Date

May 12

EPS Estimate

$-0.250

Quarterly Revenue Estimate

$1.11K

Annual Revenue
(as of Dec 31)

$41.00K